JACQUELINE KARMEL

Principal International Scientific Director, Global Medical Team Lead, Cancer Immunotherapy, Roche

Prior to this role Ms Karmel spent the previous 8 years working both as an employee and consultant for Genentech as the oncology lead for the global operational strategy for Genentech Research and Early Development (gRED). She was responsible for identifying and enabling the optimal clinical development opportunities outside of the US for both small molecules and biologics, including atezolizumab. During this time Roche acquired Genentech, at which point Ms Karmel lead the way for gRED to navigate and utilize the global wealth of country level knowledge and expertise within the multiple country affiliate offices of Roche to further assist in the operationalization of the Genentech early oncology portfolio.

Ms Karmel has over 25 years’ experience in the Biotechnology and Pharmaceutical Industry, 20 years being focused on oncology and haematology. She was the European Headquarters site co-Head for Millennium Pharmaceuticals Ltd, and Director of Clinical Operations where she worked on the successful clinical development of bortezomib for hematological malignancies as well as investigating proteasome inhibition in multiple solid tumours. She was integral to the licensing of bortezomib, which lead to partnering with Johnson and Johnson where she was part of the Joint Clinical Steering Committee.

Other key roles in oncology were at the Liposome Company where as the Lead for Clinical Operations in Europe she helped deliver the registrational study for Liposomal Doxorubicin in breast cancer, and at Eisai as an Oncology Project Manager studied cell cycle inhibitors in multiple cancer indications.